Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma

(2022) Raphaël Liévin et al.   BONE MARROW TRANSPLANTATION

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

(2022) J. Joseph Melenhorst et al.   NATURE

Granulocyte Colony-Stimulating Factor Usage in Recipients of Chimeric Antigen Receptor T-Cell Immunotherapy

(2022) Muhammad Bilal Abid   JOURNAL OF CLINICAL ONCOLOGY

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology

(2022) John A. Thompson et al.   Journal of the National Comprehensive Cancer Network

The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T ‐cell therapy

(2021) Jason N. Barreto et al.   AMERICAN JOURNAL OF HEMATOLOGY

CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma

(2021) Kai Rejeski et al.   BLOOD

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

(2021) Martina Pennisi et al.   Blood Advances

CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions

(2021) Saar Gill et al.   American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

(2021) Matthew J. Frigault et al.   BLOOD

A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma

(2021) Jae H Park et al.   BLOOD

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

(2021) Bianca D. Santomasso et al.   JOURNAL OF CLINICAL ONCOLOGY

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

(2021) Frederick L. Locke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy

(2021) Krishna R. Juluri et al.   Blood Advances

How we prevent infections in patients receiving CD19-targeted chimeric antigen receptor T-cells for B-cell malignancies

(2020) Joshua A. Hill et al.   BLOOD

G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma

(2020) Eugenio Galli et al.   BONE MARROW TRANSPLANTATION

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

(2020) Tania Jain et al.   Blood Advances

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

(2020) Qing Deng et al.   NATURE MEDICINE

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

(2020) Marcela V Maus et al.   Journal for ImmunoTherapy of Cancer

Early and late hematologic toxicity following CD19 CAR-T cells

(2019) Shalev Fried et al.   BONE MARROW TRANSPLANTATION

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

(2018) Margherita Norelli et al.   NATURE MEDICINE

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

(2018) Theodoros Giavridis et al.   NATURE MEDICINE

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

(2018) Bianca D. Santomasso et al.   Cancer Discovery

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

(2018) Rosalie M. Sterner et al.   BLOOD

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Thomas J. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and Pharmacodynamics of Pegfilgrastim

(2011) Bing-Bing Yang et al.   CLINICAL PHARMACOKINETICS

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA